The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12614000817640
Ethics application status
Approved
Date submitted
14/07/2014
Date registered
31/07/2014
Date last updated
31/07/2014
Type of registration
Retrospectively registered

Titles & IDs
Public title
How does anodal transcranial direct current stimulation of the pain neuromatrix affect brain excitability and pain perception? A randomised, double-blind, sham control study
Scientific title
The effects of anodal transcranial direct current stimulation on primary motor cortex, primary sensory cortex, and dorsolateral prefrontal cortex excitability in healthy individuals.
Secondary ID [1] 284976 0
None
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy participants- Area of research: Pain perception and the level of brain excitability 292478 0
Condition category
Condition code
Neurological 292790 292790 0 0
Studies of the normal brain and nervous system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Transcranial direct current stimulation (tDCS), including anodal (a-tDCS) and cathodal (c-tDCS), is intervention in the current project.
Since it is a new technique, the optimal parameters is unclear yet. Based on the literature, the safe current density should be less than 0.054 mV/cm2 and the duration of application should be less than 40 min.
In the current project, healthy participants received intervention with tDCS under each of five different conditions in a random order: a-tDCS of primary motor cortex , a-tDCS of primary sensory cortex, a-tDCS of dorsolateral prefrontal cortex, sham a-tDCS, and no tDCS. The experimental sessions were separated by at least 72 hours to avoid interference or carry-over effects of tDCS, and completed at the same time of day to avoid diurnal variation. The duration of tDCS application was 20 minutes with amplitude of 0.3 mA and electrode size of 1.5 * 2 cm ( current density of 0.029 mV/cm2) in all experiments.

Intervention code [1] 289804 0
Treatment: Devices
Comparator / control treatment
Sham transcranial direct current stimulation is the placebo treatment. In Sham transcranial direct current stimulation, the electrodes will be placed on the brain and the device will be turned on just for 30 second. The feeling of participants is completely similar to real (active) transcranial direct current stimulation sessions but in sham condition, there is no treatment effect.
Control group
Placebo

Outcomes
Primary outcome [1] 292644 0
The main outcome measure is the level of brain excitability in primary motor cortex. To measure the level of primary motor cortex excitability, we will use Transcranial magnetic stimulation on the primary motor cortex area and record the EMG activity of First dorsi interossous (FDI) muscle. The peak to peak amplitude of motor evoked potentials recorded from FDI muscle indicates the level of primary motor cortex excitability.
Timepoint [1] 292644 0
All evaluations will be performed before (Tpre), immediately after (T0), 30 min (T30) and 60 min (T60) after the intervention. Also, one day after the intervention all evaluations will be repeated (Tday1).
Primary outcome [2] 292689 0
The second primary outcome measure is the level of excitability in primary sensory cortex. To measure the level of excitability in the primary sensory cortex sensory evoked potential (SEP) will be measured. and the peak to peak amplitude of N20-P25 responses generated in primary sensory cortex will be measured.
Timepoint [2] 292689 0
All evaluations will be performed before (Tpre), immediately after (T0), 30 min (T30) and 60 min (T60) after the intervention. Also, one day after the intervention all evaluations will be repeated (Tday1).
Secondary outcome [1] 309413 0
Sensory threshold (STh) to electrical stimulation. Electrical stimulation will be applied by a pen electrode (model: 2762CC, Chattanooga, USA) to the right median nerve (pulse duration: 200 microsecond) at wrist level. Current supply will start at 0mA and will be increased in steps of 0.1mA until the participant reports sensation and pain. The intensity of current at which perception of the electrical stimulus is first reported will be taken as the STh.
Timepoint [1] 309413 0
All evaluations will be performed before (Tpre), immediately after (T0), 30 min (T30) and 60 min (T60) after the intervention. Also, one day after the intervention all evaluations will be repeated (Tday1).
Secondary outcome [2] 309603 0
Pain threshold (PTh) to electrical stimulation. Electrical stimulation will be applied by a pen electrode (model: 2762CC, Chattanooga, USA) to the right median nerve (pulse duration: 200 microsecond) at wrist level. Current supply will start at 0mA and will be increased in steps of 0.1mA until the participant reports sensation and pain. The intensity of current at which participants first reported pain will be taken as the PTh.
Timepoint [2] 309603 0
All evaluations will be performed before (Tpre), immediately after (T0), 30 min (T30) and 60 min (T60) after the intervention. Also, one day after the intervention all evaluations will be repeated (Tday1).
Secondary outcome [3] 309604 0
Pain threshold to the mechanical stimulation (PpTh): Pressure was induced using a pressure algometer (model: FDX 50, Wagner, USA; capacity: 50× 0.05Ibf, accuracy: ±0.3% of full scale) with a flat circular metal probe dressed in a plastic cover. Force was displayed digitally in increments of 0.1N. The algometer was mounted vertically. For each measurement the algometer was calibrated to enable force to be applied at a controlled and steady rate. PpTh was defined as the amount of force required to elicit a sensation of pain distinct from pressure or discomfort. The PpTh measurement point was marked in the middle of the belly of the FDI muscle.
Timepoint [3] 309604 0
All evaluations will be performed before (Tpre), immediately after (T0), 30 min (T30) and 60 min (T60) after the intervention. Also, one day after the intervention all evaluations will be repeated (Tday1).

Eligibility
Key inclusion criteria
All participants should be:
_ Healthy
- Right-handers as determined by the Edinburgh Handedness Inventory
_ between 18 and 49 years
Minimum age
18 Years
Maximum age
49 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
volunteers will be excluded if they have:
- Clinically significant or unstable medical, neuropsychiatric
- Chronic pain disorder
- History of substance abuse or dependence
- Any use of central nervous system-effective medication
- History of brain surgery, tumour, or intracranial metal implantation
- All participants will be interviewed and examined by a physician prior to enrolment in the study and provided written, informed consent.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Potential participants contacted the researcher by phone or email. Following this, those who wished to be sent explanatory statements and consent forms volunteer their additional contact details.
Based on the medical history forms answered by the volunteers, individuals who had no neurological or orthopaedics problem were selected and referred to the physician to be sure that application of tDCS is safe for the volunteers. Then, the second researcher allocated a number for each participants. The order of intervention sessions and the order of measuring of the outcome measures were randomized by sealed opaque envelopes.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Type of endpoint/s
Statistical methods / analysis
A two-way repeated measures ANOVA was used to assess the effects of two independent variables, site of stimulation (S1, M1, and DLPFC) and time point (Tpre, T0, and T30), on MEPs, SEPs, STh, PTh and PpTh. Mauchly’s test was used to assess the validity of the sphericity assumption for repeated measures ANOVA; it requires that the variances for each set of difference scores be equal. Greenhouse-Geisser corrected significance values were used when sphericity was lacking. Additionally, to test whether the baseline value of each stimulation site differed significantly from post-intervention time points (T0, T30), a paired-sample t-test was applied.
A significance level of P = 0.05 was adopted for all comparisons. A post-hoc test (Bonferroni) was performed where indicated. Means are reported +/- SE. Statistical analyses were performed using SPSS software version 22.

Clinically, a minimum of a 20% difference between the level of excitability before and after the intervention is needed to be sure that the intervention is effective (the magnitude of the difference between a null hypothesis and a true alternative hypothesis).
As a result, to calculate the sample size, we run a pilot study and measured the level of M1 and S1 excitability. Regarding the Power based sample size formula, the number of participants was calculated. In the current study, the power was 0.9 and Alpha was 0.05.
Based on the formula, the minimal needed participants was 11 and we recruited 12 healthy individuals.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 289599 0
Self funded/Unfunded
Name [1] 289599 0
Bita Vaseghi
Country [1] 289599 0
Australia
Primary sponsor type
Individual
Name
Shapour Jaberzadeh
Address
Building b, peninsula Campus, Monash University, Frankston, VIC, Australia
Postcode: 3199
P.O. Box: 527
Country
Australia
Secondary sponsor category [1] 288283 0
None
Name [1] 288283 0
Address [1] 288283 0
Country [1] 288283 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 291335 0
Monash University Human Research Ethics Committee (MUHREC)
Ethics committee address [1] 291335 0
Ethics committee country [1] 291335 0
Australia
Date submitted for ethics approval [1] 291335 0
Approval date [1] 291335 0
13/11/2012
Ethics approval number [1] 291335 0
CF12/2383 - 2012001295

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 49922 0
Ms Bita Vaseghi
Address 49922 0
School of Primary Health Care
Faculty of Medicine, Nursing and Health Sciences
Monash University Peninsula Campus
Building B
PO BOx 527
Frankston 3199, VIC
Country 49922 0
Australia
Phone 49922 0
+61 3 9904 4827
Fax 49922 0
+61 3 9904 4812
Email 49922 0
Contact person for public queries
Name 49923 0
Bita Vaseghi
Address 49923 0
School of Primary Health Care
Faculty of Medicine, Nursing and Health Sciences
Monash University Peninsula Campus
Building B
PO BOx 527
Frankston 3199, VIC
Country 49923 0
Australia
Phone 49923 0
+61 3 9904 4816
Fax 49923 0
Email 49923 0
Contact person for scientific queries
Name 49924 0
Bita Vaseghi
Address 49924 0
School of Primary Health Care
Faculty of Medicine, Nursing and Health Sciences
Monash University Peninsula Campus
Building B
PO BOx 527
Frankston 3199, VIC
Country 49924 0
Australia
Phone 49924 0
+61 3 9904 4816
Fax 49924 0
Email 49924 0

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseDifferential effects of cathodal transcranial direct current stimulation of prefrontal, motor and somatosensory cortices on cortical excitability and pain perception - a double-blind randomised sham-controlled study.2015https://dx.doi.org/10.1111/ejn.13043
EmbaseHow does anodal transcranial direct current stimulation of the pain neuromatrix affect brain excitability and pain perception? A randomised, double-blind, sham-control study.2015https://dx.doi.org/10.1371/journal.pone.0118340
EmbaseThe effects of anodal-tDCS on corticospinal excitability enhancement and its after-effects: Conventional vs. unihemispheric concurrent dual-site stimulation.2015https://dx.doi.org/10.3389/fnhum.2015.00533
EmbaseUnihemispheric concurrent dual-site cathodal transcranial direct current stimulation: The effects on corticospinal excitability.2016https://dx.doi.org/10.1111/ejn.13229
N.B. These documents automatically identified may not have been verified by the study sponsor.